A Phase 3b Study to Evaluate the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension
A Phase 3b Study to Evaluate the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension
This study evaluates the duration of intraocular pressure (IOP)-lowering effect and safety of as needed administrations of Bimatoprost sustained release (SR) in participants with open-angle glaucoma (OAG) or ocular hypertension (OHT) who are not adequately managed with topical IOP-lowering medication for reasons other than medication efficacy.
Inclusion Criteria:
- Diagnosis of either open angle glaucoma (OAG) (i.e., primary OAG, pseudoexfoliation glaucoma, pigmentary glaucoma) or ocular hypertension requiring intraocular pressure-lowering treatment.
Exclusion Criteria:
San Antonio, Texas 78240, United States
CABA, Buenos Aires 1122, Argentina
Ciudad de Buenos Aires, Buenos Aires F.D. 1116, Argentina
Ciudad Autonoma Buenos Aires, 1033, Argentina
Sofiya, Sofia 1407, Bulgaria
Sofiya, Sofia 1431, Bulgaria
Sofia, 1408, Bulgaria
Kiel, Schleswig-Holstein 24105, Germany
Gdansk, Pomeranian Voivodeship 80-809, Poland
Olsztyn, Warmian-Masurian Voivodeship 10-424, Poland
Novosibirsk, Novosibirsk Oblast 630071, Russia
Somerset West, Western Cape 7130, South Africa
London, Greater London SE5 9RS, United Kingdom
Oxford, Oxfordshire OX3 9DU, United Kingdom